- #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapyBOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…Endpoints · 2mo ago↗ source
- Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boostMerck KGaA appears to have a big-picture view of how the Iran war is affecting the pharma industry so far. The German company is seeing an uptick in demand for its lab equipment products as ...Endpoints · 2mo ago↗ source
- Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance optionsReducing the dose of Eli Lilly’s obesity shot Zepbound could provide a safe, effective and potentially cheaper option for the maintenance of weight loss, according to new data. The findings come…